Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Casirivimab+imdevimab for COVID-19 prevention in immunocompromised patients
NCT05074433Phase 3Terminated
- Sponsor
- Regeneron Pharmaceuticals
- Start
- Oct 2021
- Primary completion
- May 2022
- Modality
- Monoclonal Antibodies
- Countries
- 2
01
Overview
A Phase 3 trial of casirivimab + imdevimab in coronavirus disease 2019 (COVID-19), sponsored by Regeneron Pharmaceuticals. Started Oct 2021; status: terminated.
02
Drugs
casirivimab + imdevimab
03
Conditions
coronavirus disease 2019 (COVID-19)
Beyond the preview
Go deeper on NCT05074433.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05074433.